Related Experiment Video
Updated: Jul 19, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Biopharmaceutical therapeutics for asthma remodeling.
A M Das1, D E Griswold, T J Torphy
1Immunobiology, Centocor Inc., 145 King of Prussia Road, Radnor, PA, USA. adas2@cntus.jnj.com
Current Pharmaceutical Design
|October 6, 2006
Summary
Current asthma treatments control symptoms, but some patients remain symptomatic. New biopharmaceutical therapies targeting airway remodeling, specifically subepithelial fibrosis, are needed to address this unmet medical need in asthma.
Area of Science:
- Pulmonology
- Cellular Biology
- Pharmacology
Background:
- Current asthma therapies primarily focus on symptom management.
- A significant subset of asthma patients experience persistent symptoms despite optimal treatment, indicating an unmet medical need.
- Airway remodeling is increasingly recognized as a key contributor to asthma pathology.
Purpose of the Study:
- To review the contribution of subepithelial fibrosis to airway remodeling in asthma.
- To explore potential mechanisms driving subepithelial fibrosis.
- To identify molecular targets for novel asthma therapeutics.
Main Methods:
- Literature review of current research on asthma, airway remodeling, and subepithelial fibrosis.
- Analysis of proposed mechanisms involved in the development of subepithelial fibrosis.
- Identification and discussion of potential therapeutic targets based on mechanistic insights.
Main Results:
- Subepithelial fibrosis is a significant component of airway remodeling in asthma.
- Several molecular pathways are implicated in the pathogenesis of subepithelial fibrosis.
- Specific molecular targets within these pathways show promise for therapeutic intervention.
Conclusions:
- Targeting subepithelial fibrosis represents a promising strategy for developing innovative asthma therapies.
- Biopharmaceutical approaches offer potential for identifying and developing agents to treat this aspect of asthma.
- Further research into the identified molecular targets is warranted to address the unmet medical needs in asthma management.
Related Concept Videos
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms: